Clinical Data Double-Boost Supports Medtronic's HeartWare Investment
Executive Summary
Results of the LATERAL trial presented at the recent ISHLT conference show Medtronic's HVAD can be implanted safely through a thoracotomy procedure instead of the standard sternotomy approach, which is far more invasive. At the same meeting, subset data from the ENDURANCE trial confirms that the sickest heart-failure patients treated with HVAD have similar outcomes as less sick patients, and results of the ENDURANCE Supplement show that blood pressure management minimizes the risk of stroke with HVAD.
You may also be interested in...
Cost-Effectiveness Studies Support Medtronic's HeartWare HVAD
A cost-effectiveness analysis of the LATERAL trial shows patients treated with Medtronic’s HeartWare HVAD through the less-invasive thoracotomy procedure incurred lower hospitalization and medical supply costs than patients implanted with a ventricular assist device through the traditional sternotomy approach. Another new analysis shows HeartWare HVAD is more cost-effective than ventricular assist devices of the past.
US FDA Approves Medtronic's HVAD For Destination Therapy
The expanded labeling gives Medtronic's HVAD, acquired when it bought HeartWare last summer, the same indication as Abbott's HeartMate II ventricular assist device.
Medtronic Set To Compete With Abbott/St Jude In VADs After Buying HeartWare
HeartWare has found a way to pay for the expanded commercialization of its HVAD ventricular assist device and the development of its MVAD miniaturized ventricular assist device; the Boston-area VAD-maker has agreed be acquired by medtech giant Medtronic for $1.1bn in cash.